Detalhe da pesquisa
1.
Mutational hotspots lead to robust but suboptimal adaptive outcomes in certain environments.
Microbiology (Reading)
; 169(10)2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37815519
2.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910333
3.
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
BMC Cancer
; 19(1): 582, 2019 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200667
4.
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
BMC Cancer
; 19(1): 1102, 2019 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727024
5.
Experiences of establishing an academic early phase clinical trials unit.
Clin Trials
; 14(4): 349-356, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28532202
6.
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Br J Haematol
; 170(3): 336-48, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891006
7.
The Truth about Sugar.
Dent Update
; 42(6): 507-10, 512, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26506805
8.
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).
Br J Haematol
; 185(3): 573-578, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30125960
9.
Investigation of molecular alterations of AKT-3 in triple-negative breast cancer.
Histopathology
; 64(5): 660-70, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24138071
10.
A mutational hotspot that determines highly repeatable evolution can be built and broken by silent genetic changes.
Nat Commun
; 12(1): 6092, 2021 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34667151
11.
A meta-analysis of the use of intraoperative cholangiography; time to revisit our approach to cholecystectomy?
Surg Open Sci
; 3: 8-15, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33937738
12.
MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.
BMJ Open
; 11(3): e046225, 2021 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762245
13.
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
Clin Lymphoma Myeloma Leuk
; 21(3): 154-161.e3, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33478922
14.
Effects of clusterin over-expression on metastatic progression and therapy in breast cancer.
BMC Cancer
; 10: 107, 2010 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20307318
15.
Readmission to hospital following laparoscopic cholecystectomy: a meta-analysis.
Anaesthesiol Intensive Ther
; 52(1): 47-55, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32090306
16.
Assessing the impact of the 2018 American Society of Clinical Oncology/College of American Pathologists recommendations on human epidermal growth factor receptor 2 testing by fluorescence in situ hybridization in breast carcinoma.
Virchows Arch
; 476(3): 367-372, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31375912
17.
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Trials
; 21(1): 826, 2020 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33008427
18.
CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.
Trials
; 21(1): 89, 2020 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31941523
19.
SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective.
Br J Radiol
; 90(1073): 20160637, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28291381
20.
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Lancet Haematol
; 3(12): e572-e580, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27843120